12:00 AM
 | 
Jul 23, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Dacogen decitabine regulatory update

EMA's CHMP recommended approval of an MAA from Johnson & Johnson for Dacogen to treat newly diagnosed de novo or secondary acute myelogenous leukemia (AML) in patients 65 years...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >